GleamWall
中文EN

MBIO MUSTANG BIO, INC.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1680048 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-51.1%
TTM EPS YoY92.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-43.1%
ROA-20.7%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets55.1%
Debt / equity0.00x
Current ratio—
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.29x
Accruals ratio6.1%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense—$7.56M
SG&A expense$3.95M$4.13M
Operating income-$2.43M-$16.25M
Interest expense—$5,000
Pretax income-$1.92M-$15.75M
Income tax$27,000—
Net income-$1.92M-$15.75M
EBITDA-$2.40M-$15.57M
EPS (basic)-0.39-38.57
EPS (diluted)-0.39-38.57
Weighted avg. shares (diluted)4.91M609,696
Balance sheet
Cash & equivalents$17.27M$6.84M
Current assets$17.59M$8.61M
PP&E, net$0$371,000
Total assets$17.59M$9.31M
Current liabilities$7.91M$12.61M
Total liabilities$8.06M$13.18M
Shareholders' equity$9.53M-$3.87M
Cash flow statement
Operating cash flow-$5.26M-$11.41M
Capital expenditure—$0
Free cash flow—-$11.41M
Investing cash flow$1.17M$0
Financing cash flow$14.53M$11.27M
Depreciation & amortization$34,000$671,000
Stock-based compensation$129,000-$450,000

Free plan shows the latest 2 periods; Pro shows all 10 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.